Navigating Cancer Communication on Twitter
Twitter is increasingly being used by oncologists as a tool to communicate advancements in in the treatment of cancer. What could go wrong?
Chronic Myeloid Leukemia
CHRONIC MYELOID LEUKEMIA ADVISOR
FEATURED CONTENT
-
-
Wider Use of Basket Trials Could Hasten Development of Precision Therapies
Basket trials are those that test investigational therapies in patients who have different types of cancer but share a particular genomic aberration. -
Should the FDA Do More to Increase Transparency?
An FDA pilot program to promote transparency in clinical studies falls short of similar efforts by its European and Canadian counterparts. -
Unlocking the Potential of Biosimilars in Community Oncology
Full adoption of biosimilars will require proper provider and patient education, payer coverage navigation support, and streamlined workflows. -
Can Patient-Derived Organoids Help Oncologists Make Treatment Decisions?
Organoids created from tumor samples have been revolutionizing laboratory research, but they also may begin helping oncologists decide on treatment regimens for patients.
VIDEO SERIES
Ponatinib for CML
Progress in the CML Landscape
Treatment Options
Sequencing Treatment
Choosing the Appropriate TKI
Monitoring Treatment Response
Monitoring Adherence
Switching Therapies
Discontinuing Treatment
Known Factors in TKI Resistance
Managing Adverse Events
Allogeneic Stem Cell Transplant
CML: On the Horizon
The Future of CML Treatment
CHRONIC MYELOID LEUKEMIA NEWS
Second-Generation TKIs in Advanced CML: 7-Year Survival Rates
Generic Imatinib Compared With Gleevec in CP-CML: Patient Outcomes Across 3 Countries
Prototype Intervention Increased Adherence to TKIs in CML
Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia
New Combo for Chronic Myeloid Leukemia Shows Activity In Vitro
Want to read more?
Please login or register first to view this content.
Next post in Chronic Myeloid Leukemia
